Lex­i­con 3-for-3 in PhI­II for a new di­a­betes pill, rack­ing up a clean sweep un­der $1.7B Sanofi pact

Lex­i­con Phar­ma­ceu­ti­cals $LXRX is now three-for-three in its Phase III pro­gram for so­tagliflozin, set­ting up reg­u­la­to­ry ap­pli­ca­tions for this Sanofi-part­nered ther­a­py as the first pill …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER